Harrow
Adrienne Graves serves as an Independent Director and Board Member for multiple organizations, including Osanni Bio, Harrow, NVasc, Implandata Ophthalmic Products, Ocular Therapeutix, Inc., and JelliSee, among others, showcasing extensive leadership experience in the healthcare and biotechnology sectors. Graves holds a doctorate in Visual Neuroscience from the University of Michigan, supplemented by a postdoctoral fellowship from Université de Paris. A graduate of Brown University with a Bachelor's Degree, Graves has maintained an active role in the American Society of Cataract and Refractive Surgery since 2009.
This person is not in any teams
This person is not in any offices
Harrow
2 followers
Harrow (Nasdaq: HROW) is a leading U.S. eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic prescription therapies that are accessible and affordable. Harrow owns U.S. commercial rights to ten FDA-approved ophthalmic pharmaceutical products. Harrow also owns and operates ImprimisRx, the leading U.S. ophthalmic‑focused pharmaceutical compounding business, which also serves as a mail-order pharmacy licensed to ship prescription medications in all 50 states. Harrow has non-controlling equity positions in Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc., companies that began as subsidiaries of Harrow. Harrow also owns royalty rights in four late-stage drug candidates being developed by Surface and Melt.